SynthesisBMC nephrology2025
How serious is the risk of HTLV-1 infection in Iranian hemodialysis-dependent patients?
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Seroprevalence of human T-cell lymphotropic virus and transfusion-transmitted viral hepatitis markers among hemodialysis and thalassemia patients in the South of Iran.BMC infectious diseases · 2026Article
- Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe transmission of infectious agents through hemodialysis is one of this critical treatment's most significant side effects. Human T-lymphotropic virus 1 (HTLV-1) is an endemic oncogenic virus in Iran. Due to its relatively lower prevalence, the infection with this virus is not routinely screened for in patients before hemodialysis. In this study, we aimed to evaluate the seropositivity of HTLV-1 in hemodialysis-dependent patients of Iran to better understand how this treatment can help the virus spread.
methodsA comprehensive systematic review and meta-analysis were performed by searching PubMed, Scopus, Google Scholar, and Web of Science databases for studies on the prevalence of HTLV-1 among hemodialysis-dependent patients. The meta-analysis was conducted using R.
resultsTwelve studies were included. Overall, the prevalence of HTLV1 among patients dependent on hemodialysis treatment was 2.37% (I2 = 70.8% /p-value < 0.0001). The funnel plot asymmetry and trim and fill analysis results showed three studies with higher prevalence as outlier results which all were originated in endemic region of Iran, Khorasan. Highlighting the higher prevalence in the endemic areas.
conclusionConsidering the significantly higher prevalence of infection with HTLV-1 in hemodialysis-dependent patients compared to the general population of Iran, more efforts seem necessary to prevent the transmission of the virus through this treatment, even considering screening protocols similar to blood transfusion protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.